Security Snapshot

Traws Pharma, Inc. - Common Stock, $0.01 par value (TRAW) Institutional Ownership

CUSIP: 68232V884

13F Institutional Holders and Ownership History from Q3 2024 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

18

Shares (Excl. Options)

4.78MFull value: 4,778,767 · shares · 30 Sep 2026

Price

$0.59

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
-248,947
Value change
-$173,774
Number of holders
18
Issuer context Names, identifiers, and filing context for this profile. 2 identity fields
Shares outstanding
66,317,919
SEC-reported price per share
$0.30
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • TRAW - Traws Pharma, Inc. - Common Stock, $0.01 par value is tracked under CUSIP 68232V884.
  • 18 institutions reported positions in Q3 2026.
  • 7 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 33 to 18 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $5.19MFull value: $5,190,728 · USD · 30 Jun 2026
    to
    $2.84MFull value: $2,836,375 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 18 institutions filings for Q3 2026.

Open SEC evidence

Security key

68232V884

13F reference period

Q3 2026

13F holders

18

13D/G owners

7

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
7
Security
TRAW
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Sirenia Capital Management LP 9.9% $4,464,522 6,565,474 Sirenia Capital Management LP 30 Jun 2026
ORBIMED ADVISORS LLC 12% -40% $3,431,754 +$2,040,131 1,876,198 +147% ORBIMED ADVISORS LLC 16 Apr 2026
Ikarian Capital, LLC 9.5% -4.9% $1,057,688 +$505,171 1,555,423 +91% Ikarian Capital, LLC 30 Jun 2026
PERCEPTIVE ADVISORS LLC 6.1% -39% $1,793,061 +$170,058 979,815 +10% Perceptive Advisors LLC 31 Mar 2026
Adage Capital Management, L.P. 4.8% -48% $496,400 730,000 0% Adage Capital Management, L.P. 30 Jun 2026
Ayrton Capital LLC 4.3% -56% $552,125 -$97,751 342,935 -15% Ayrton Capital LLC 31 Dec 2025
Alyeska Investment Group, L.P. 9.9% $462,446 302,252 Alyeska Investment Group, L.P. 31 Dec 2024
As of 30 Sep 2026, 18 institutional investors reported holding
4.78MFull value: 4,778,767 · shares · 30 Sep 2026
shares of Traws Pharma, Inc. - Common Stock, $0.01 par value (TRAW). This represents 7.2% of the company’s total
66.32MFull value: 66,317,919 · shares · Stored outstanding share count
outstanding shares.

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
9
Headline period
Q3 2026
Rows shown
1-9 of 9
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 4,778,767 $2,836,375 -$173,774 $0.59 18
2026 Q2 6,156,329 $5,190,728 +$1,553,904 $0.84 33
2026 Q1 3,619,796 $6,624,230 +$459,630 $1.83 27
2025 Q4 3,418,588 $3,863,003 +$1,409,923 $1.13 21
2025 Q3 1,304,595 $2,413,244 +$101,966 $1.85 18
2025 Q2 1,263,487 $1,869,962 -$1,075,287 $1.48 19
2025 Q1 1,732,309 $3,984,315 +$1,207,345 $2.30 18
2024 Q4 1,141,975 $10,140,752 +$4,400,867 $8.88 17
2024 Q3 646,356 $3,800,574 +$3,742,033 $5.88 10
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .